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Abstract: Crohn’ disease (CD) patients are at high risk of postoperative recurrence and new tools
for the assessment of disease activity are needed to prevent long-term complications. In these
patients, the over-production of ROS generated by inflamed bowel tissue and inflammatory cells
activates a pathogenic cascade that further exacerbates inflammation and leads to increased oxidative
damage to DNA, proteins, and lipids. We measured the products of protein/lipid oxidation and
the total antioxidant capacity (ferric reducing ability of plasma, FRAP) in the serum of CD patients
with severe disease activity requiring surgery with the aim to characterize their redox status and
identify associations between oxidative stress-related markers and their clinical characteristics. At the
systemic level, CD was associated with increased levels of protein and lipid oxidation products when
compared to healthy volunteers, even though the FRAP values were similar. Advanced oxidation
protein product (AOPP) levels showed the highest difference between patients and the controls
(11.25, 5.02–15.15, vs. 1.36, 0.75–2.70, median, interquartile range; p < 0.0001) and the analysis of
receiver operating characteristic (ROC) curves, indicated for AOPP, the best area under the curve
(AUC) value for CD prediction. Advanced glycated end-products (AGEs) were also significantly
higher in CD patients (p < 0.01), which is of interest since AOPP and AGEs are both able to activate
the membrane receptor for advanced glycation end products (RAGE) involved in inflammatory
diseases. Thiobarbituric acid reactive substance (TBARS) levels were significantly higher in CD
patients with ileal localization and aggressive disease behavior, in smokers, and in patients suffering
from allergies. In conclusion, our data indicate that circulating oxidative stress biomarkers may be
attractive candidates as disease predictors as well as for clinical or therapeutic monitoring of CD. Our
results also suggest that AOPP/AGEs and RAGE signaling may represent a pathogenic factor and a
potential therapeutic target in CD.
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1. Introduction
Crohn’s disease (CD) is a chronic inflammatory disorder of the intestinal tract, with increasing
prevalence worldwide [1,2]. It is generally accepted that CD as well as ulcerative colitis (UC) are
the result of complex interactions among environmental factors, dysregulated immune system, gut
microbiota, and disease susceptibility genes [3]. Accumulating data suggest that oxidative stress is at
the crossroad between these multiple mechanisms [4–6].
Both chronic inflammation and immune system hyperactivation are accompanied by abnormally
high levels of reactive oxygen species (ROS) and decreased antioxidant defenses, resulting in oxidative
stress. Oxidative stress leads to mucosal layer damage and bacterial invasion, which in turn further
stimulate the immune response and contribute to disease progression [7]. One of the main advantages
of oxidative modifications of cellular proteins, lipids, and nucleic acids is that they can be measured not
only in the affected intestinal tract, but also at the systemic level; several studies have in fact reported
increased levels of oxidative stress biomarkers in the serum/plasma of inflammatory bowel disease
(IBD) patients [8]. This is of interest at least for two reasons: on one hand, circulating biomarkers of
oxidative stress offer the advantage of easy collection, low costs, and the possibility to be used on a
large scale; on the other hand, the systemic oxidative stress observed in CD may likely contribute to
the development of extra-intestinal manifestations such as perianal fistulas, dermatologic diseases,
and arthritis, which are very common in these patients [9].
Circulating antioxidant capacity also seems to be correlated with the clinical status of the patients.
Plasma free thiols were recently reported to be associated with favorable outcome in CD, being
negatively correlated with biomarkers of inflammation [10], and serum free thiols and uric acid
were significantly lower in active CD patients with anemia [11]. Furthermore, a very strong positive
correlation was found between the endoscopic activity index and the serum total oxidant status in CD
patients under regular follow-up [12]. These data suggest that the measure of circulating oxidative
stress markers might be clinically useful both for early diagnosis as well for clinical monitoring. Clinical
diagnosis of CD can be complex and it is often delayed. Moreover, CD patients need an adequate
assessment of disease activity either to guide clinical treatment, prevent long-term complications, or
induce a long-term remission after surgery.
On these bases, the aim of the present study was to explore the association between several
peripheral biomarkers of oxidative stress and the clinical characteristics of a cohort of CD patients
characterized by therapeutic failure and a complicated disease requiring surgery.
2. Methods
2.1. Study Population
The study protocol was approved by the Ethical Review Committee of the Hospital of Careggi,
Florence, Italy. Written informed consent was obtained from all eligible participants. A total of
71 subjects (54 patients with CD and 17 controls) were included in this observational study. Patients
were recruited between January 2015 to January 2017 at the Digestive Surgery Unit of the Careggi
Hospital, where all had severe relapse (CD activity index scores of >200) requiring surgery. The healthy
volunteers were recruited among the personnel of the Careggi Hospital. Serum was obtained from
blood samples, taken at surgery for CD patients or at enrolment for the control subjects, collected in
Vacutainer®collection tubes, coagulated at room temperature, and centrifuged at 1800× g for 10 min
before the distribution of the supernatant in cryo-tubes, and stored at −20 ◦C until analysis.
Information on gender, age, disease duration, diagnostic delay, smoking habits, location,
disease behavior, extra-intestinal manifestation, perianal disease, recurrence, number of operations,
immunological comorbidity, familiarity IBD, and therapy were collected. Demographic and clinical
characteristics of CD patients and healthy controls are reported in Table 1.
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Table 1. Demographic and clinical characteristics of Crohn’s patients and healthy volunteers enrolled
in the study.
Demographic and Clinical Characteristics Crohn’s Patients Controls
n 54 17
Gender
-male 28 (51.9%) 7 (41.2%)
-female 26 (48.1%) 10 (58.8%)
Age (years) 42.12 ± 2.055 42.41 ± 3.73
Disease duration (years) 12.86 ± 1.37
Diagnostic delay (months) 78.89 ± 16.32
Smoke habit
no 19 (38.0%) 8 (47.1%)
yes 16 (32.0%) 5 (29.4%)
former 15 (30.0%) 4 (23.5%)
CDAI 233.6 ± 5.66
Disease location
-Ileum 28 (53.8%)
-Colon 18 (34.6%)
-Ileo-colon 6 (11.5%)
Disease behavior
-Inflammatory 4 (7.5%)
-Stricturing 28 (52.8%)
-Fistulizing 3 (5.7%)
-Stricturing and Fistulizing 18 (34.0%)
Extra-intestinal disease
-Skin 7/46 (15.21%)
-Arthritis 12/46 (26.1%)
Perianal disease yes/no 23/28 (45.10%)
Recurrence
-yes 30 (57.69%)
-no 22 (42.31%)
Multiple operations
1 22 (42.31%)
2 15 (28.85%)
3 15 (28.85%)
Allergies yes/no 19/25 (43.2%)
Familial IBD yes/no 15/34 (30.6%)
CDAI = Crohn disease activity index. Data are means ± SE or absolute and relative frequencies.
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2.2. Ethics Approval and Consent to Participate
This study was approved by the Ethical Committee of Careggi-University Hospital (AOUC),
Florence, Italy, on May 2, 2011, protocol no. 2011/0016888, rif. 95/10, authorization Gen Dir 17/572011
protocol no. 2011/0018055, and written informed consent was obtained from all study subjects.
2.3. Ferric Reducing Activity of Plasma (FRAP)
A FRAP reagent solution was freshly prepared by mixing 300 mM acetate buffer, pH 3.6, TPTZ
solution (10 mM 2,4,6-tripyridyl-s-triazine (TPTZ) in 40 mM HCl), and 20 mM FeCl3·6H2O in a volume
ratio of 10:1:1. To perform the assay, 0.9 mL of FRAP reagent, 90µL of distilled water, and 30µL of serum
were mixed and incubated at 37 ◦C for 30 min. The absorbance was measured at 595 nm. The antioxidant
potential of samples was determined from a standard curve plotted using the FeSO4·7H2O [13].
2.4. Advanced Oxidation Protein Product (AOPP)
For AOPP determination, 20 µL of serum and 980 µL of PBS were mixed to 50 µL of KI 1.16 M
and 100 µL of acetic acid. The absorbance of the reaction mixture was immediately read at 340 nm.
AOPP were quantified in µmol/mg of proteins using Chloramine-T (Sigma-Aldrich, Milan, Italy) as the
standard for the calibration curve [14].
2.5. Carbonyl Residues (CO)
Carbonyl residues were determined following the method of Correa-Salde and Albesa [15] with
a few modifications. Serum samples (100 µL) were treated for 1 h at room temperature with 900 µL
of 0.1% dinitrophenylhydrazine in 2 M HCl and precipitated with 400 µL of 10% trichloroacetic acid
(TCA) before being centrifuged for 20 min at 4 ◦C at 10,000× g. The pellets were extracted with 500 µL
of ethanol:ethyl acetate mixture (1:1) and centrifuged for 3 min at 4 ◦C at 10,000× g, three times and
then dissolved in 15 mL of 6 M guanidine HCl in 20 mM potassium phosphate buffer (PBS), pH 7.5.
The solutions were incubated at 37 ◦C for 30 min and insoluble debris was removed by centrifugation.
The absorbance was measured at 370 nm.
Carbonyl content was calculated using a molar absorption coefficient of 22,000 M−1 cm−1 and
expressed as nmol/mg of proteins. Protein content was estimated by using the Bio-Rad DC protein
assay kit (Bio-Rad, Segrate, Milan, Italy).
2.6. Thiobarbituric Acid Reactive Substances (TBARS)
TBARS were evaluated as an index of lipid peroxidation according the method by
Dietrich-Muszalska et al. [16]. A total of 100 µL of serum was first deproteinized by adding 100 µL
of TCA, then 160 µL was added to 32 µL of 0.12 M thiobarbituric acid (Sigma-Aldrich, Milan, Italy)
in TRIS 0.26 M, and heated for 15 min at 100 ◦C. The reaction was stopped by placing the vials in
an ice bath for 10 min and after centrifugation (at 1600× g at 4 ◦C for 10 min), the absorbance of the
supernatant was measured at 532 nm (Perkin Elmer Wallac 1420 Victor3 Multilabel Counter).
TBARS content was calculated using a molar absorption coefficient of 1.56 × 10−5 M−1 cm−1 and
expressed as µM.
2.7. Advanced Glycated End-Products (AGEs)
AGEs were determined by exploiting the characteristic autofluorescence of the large part of AGEs
as described by Cournot and Burillo [17]. A total of 100 µL of 1:5 diluted in PBS serum, were placed in
a 96-well plate and the fluorescence intensity was read at 460 nm, after excitation at 355 nm. Results
were expressed as arbitrary units (AU).
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2.8. Statistical Analyses
Statistical analyses were performed using Statgraphics Centurion XVI software and Graph-Pad
Prism 7.00. p-values less than 0.05 were considered statistically significant. Normality was verified
with the Kolmogorov–Smirnov test. Normally distributed and continuous variables were expressed as
means ± standard deviation (SD). Non-normally distributed variables were expressed as median and
interquartile range. Comparison of continuous variables between the two groups were performed
using the Student’s t-test (normally distributed) or Mann–Whitney test (non-normally distributed).
Differences between proportions were assessed using the chi-square or Fisher exact test.
The area-under-curve (AUC) of the receiver operating characteristic (ROC) curves for each
oxidative stress biomarker were used to characterize their utility for discriminating CD patients from
healthy subjects.
A stepwise multiple linear regression analysis with backward selection was performed with
oxidative stress markers as the dependent variables and the following factors as independent variables:
age at surgery, gender, diagnostic delay, smoke habit, CDAI, disease location, disease behavior, disease
duration, extra-intestinal disease, perianal disease, first clinical presentation, recurrence, number of
surgeries, allergies, and family history of IBD.
An oxidative score was calculated and consisted of four components. For oxidative markers
(TBARS, CO, AGEs, and AOPP) values below the median value were assigned 0 point and those above
the median value, 1 point. For FRAP values, the point assignment was the reverse (0 below the median
and −1 above the median value). According to the sum of the four components, patients were allocated
to three oxidative score categories: low, medium, and high.
3. Results
3.1. Baseline Characteristics
No significant differences in age, gender, and smoke habit distribution were observed between
CD patients and the control group.
At the time of surgery for CD, 16 patients were smokers, 15 former smokers, and 19 had never
smoked. In about 54% of the patients, the disease was localized in the ileum, in 34.6% in the colon and
only 6 (11.5%) patients had a disease involving both segments. Many of the patients (41%) presented
extra-intestinal diseases (skin and arthritis), 45.10% perianal disease, 55.5% had already undergone
surgery, and in 30.6% of the cases, familial IBD was observed.
3.2. Oxidative Damage and Antioxidant Capacity
All of the oxidative damage parameters measured were significantly higher in the serum of CD
patients when compared to the controls (Table 2). In particular, the difference between the AOPP levels
in the serum of CD patients was very high when compared to healthy volunteers with a median value
of 11.25 (5.02–15.15) vs. 1.36 (0.75–2.70) µmol/g of proteins, respectively (Table 2 and Figure 1A).
Based on the analysis of ROC curves, we assessed the diagnostic utility of the oxidative damage
biomarkers as predictors of CD. The area under the ROC curve (AUC) was 0.6938 for TBARS, 0.7412
for CO, 0.7195 for AGEs, and 0.5765 for FRAP. The AOPP determination resulted in a much higher
AUC value of 0.9306 for the prediction of Crohn’s disease (Figure 1B).
The antioxidant capacity, measured as FRAP values, in the CD patients and controls was similar
(Table 2).
Through univariate analysis, we observed that CD patients treated with azathioprine (n = 24)
presented FRAP levels significantly higher (p < 0.05) than those untreated (n = 18). Moreover, serum
AOPP levels were significantly reduced in patients treated with mesalazine (p < 0.01), but the number
of untreated patients was very low (6 vs. 41).
Antioxidants 2019, 8, 378 6 of 12
Table 2. Mean values of oxidative markers in serum samples from Crohn’s patients or healthy volunteers.
Oxidative Markers Crohn’s Patients Controls
n 54 17
FRAP, µM Fe2+ 368.2 ± 90.72 343.8 ± 100.30 NS
TBARS, µM 4.00 ± 1.35 3.11 ± 0.45 p < 0.01
AGEs, AU 293.3 ± 108.80 216.0 ± 35.03 p < 0.01
AOPP, µmol/g of proteins 11.25 (5.02–15.15) 1.36 (0.75–2.70) p < 0.0001
CO, nmol/mg of proteins 0.122 (0.095–0.146) 0.074 (0.061–0.12) p < 0.01
Means ± SD or median (interquartile range 25–75); p-values by t test or by Mann–Whitney test. AU: Arbitrary Units.
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for AOPP.
Positive correlations existed among almost all of the different markers of oxidative stress, both
in the CD patients and in the controls (Tables S1 and S2). Figure 2 shows the correlation between
circulating AOPP and TBARS levels in CD patients. No correlation between CDAI and oxidative-stress
parameters was observed.
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3.3. Multiple Regression Analysis
Multiple regression analysis identified five independent variables associated with circulating
TBARS in CD patients; in contrast, the other oxidative stress biomarkers did not show significant
associations with clinical parameters. By backward stepwise regression, TBARS were associated to the
disease site, behavior, and first clinical presentation, being higher in patients with an ileal localization
of the disease, with a fistulizing and stricturing behavior and with the severity of the first clinical
presentation (combination of occlusion, anemia, and weight loss or the presence of perianal fistulas).
Moreover, TBARS were also associated with the smoke habit and with the presence of allergies (Table 3).
The oxidative score was associated with smoke habit (p = 0.013) and with the presence of a skin
extension of the disease (p = 0.0245) (Table 4).
Table 3. Multiple regression analysis of factors associated with circulating TBARS in Crohn’s patients.
Parameter Estimate Coefficient p-Value
CONSTANT 1.89611 0.0113
Disease Location −0.63005 0.0185
First Clinical Presentation 0.270233 0.0089
Smoking 0.865863 0.0005
Disease Behavior 0.383783 0.0275
Allergies 0.997169 0.0001
Table 4. Multiple regression analysis of factors associated with the oxidative score in Crohn’s patients.
Parameter Estimate Coefficient p-Value
CONSTANT 0.490099 0.0159
Smoking 0.420792 0.0113
Skin Extension 0.782178 0.0245
4. Discussion
Accumulating evidence indicates that oxidative stress is not only merely a consequence of chronic
inflammation, but may have an essential role in the development and maintenance of inflammation
and aberrant immune response in CD. In this regard, our results demonstrate an overall increase in
oxidative stress biomarkers in CD patients at surgery when compared to the controls, highlighting that
severe clinical activity is reflected by systemic oxidative stress. Among the markers analyzed, AOPP
demonstrated the greatest diagnostic ability in differentiating CD patients from the controls. AOPPs are
di-tyrosine-containing and cross-linking products, formed by the reaction of plasma proteins, mainly
albumin, with chlorinated compounds resulting from the activity of myeloperoxidase (MPO) [14,18].
For this reason, AOPP are recognized as both oxidative protein damage markers and mediators
of inflammation.
Increased plasma AOPP levels in patients with chronic diseases including active CD patients
have been reported by others [19–21]. In our study, CD patients had very high levels of AOPP in their
serum, much higher when compared to the study by Krzystek-Korpacka and co-workers [20], who
measured a mean level of 1.87 µmol/g of albumin in the plasma of active CD patients. We measured
AOPP levels in the serum of CD patients at surgery, therefore with severe clinical conditions, and these
high levels can be a consequence of their clinical status.
Interestingly, some mechanistic studies have demonstrated the role of AOPP in the pathogenesis
and progression of CD. There is in fact in vitro and in vivo evidence that AOPPs induced depletion of
intestinal epithelial cells and inflammatory changes that alter the structural integrity of the intestinal
mucosa [22–24]. These compounds are also able to modulate cell cycle arrest [25]; Shi and co-worker
Antioxidants 2019, 8, 378 8 of 12
recently demonstrated that AOPPs exhibit their negative regulatory function on intestinal epithelial
cell cycle progression by activating the RAGE/CD36-c-jun N-terminal kinase (JNK)-p27kip1 signaling
pathway [21]. By interacting with RAGE and CD36 receptors, AOPP activate protein kinase C and
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase as well as the NF-κB-dependent
inflammatory pathway [26]. Xu et al. [27] also found that the deposition of AOPPs in fibrotic lesions from
CD patients promoted epithelial–mesenchymal transition, a fundamental mechanism in complications
of CD such as intestinal fibrosis through the oxidative and inflammatory pathway.
Other than AOPP, the first identified ligands of RAGE were AGEs. Although RAGE/AGE signaling
has mainly been studied in diabetes, there is also evidence of its activation in neurodegenerative
diseases, cancer, and in various inflammatory diseases including CD [28–30]. Mice lacking RAGE
receptors are in fact protected from chemically-induced intestinal inflammation and treatment with
a RAGE-specific inhibitor protects mice from indomethacin-induced enteritis and dextran sulfate
sodium-induced colitis, suggesting that the RAGE signaling pathway could be a promising therapeutic
target for IBD patients [30]. On the contrary, there are no reports available in the literature on the
serum level of AGEs in patients with CD. AGEs are heterogeneous compounds mainly generated
through the non-enzymatic glycation of protein, lipids, and nucleic acid driven by hyperglycemia
and oxidative stress, but increased serum levels were associated with hypercholesterolemia [31]
and cigarette smoking [32]. In addition, humans are exposed to dietary sources of AGEs through
animal-derived foods and cooking processes that result in the formation of new AGEs [33]. Moreover,
AGEs such as glycol aldehyde and 2-hydroxy-propanal may be generated by activated neutrophils,
even in the absence of sugars [34].
Lipid peroxidation products are also implicated in the pathogenesis of IBD. For instance, it
has been reported that 4-hydroxynonenal treatment suppressed colonic expression of tight junction
proteins, enhanced bacterial translocation from the gut into the systemic circulation, and increased
activation of Toll-like receptor 4 signaling [35].
In our cases, circulating TBARS were significantly higher when compared to the controls and
these results are in line with those obtained by others who measured elevated lipid peroxidation
markers malondialdehyde (MDA)/TBARS in CD patients [35–38]. In the study by Sampietro and
co-workers, CD patients at surgery showed a significantly higher basal peroxidative state when
compared to the controls, but while the inflammatory and oxidative indices were significantly reduced,
two months later, and maintained low one year after surgery, TBARS did not reach levels comparable
to those in the control subjects, indicating that in quiescent CD, there is an upregulated level of plasma
peroxidation [39].
Szczeklik and co-workers recently described the presence of an upward trend in the serum (and
saliva) MDA levels, depending on the severity of CD and a correlation between the MDA levels and
the visible symptoms of inflammation [40]. Our results showed a significant correlation among lipid
peroxidation, disease location, and behavior and with the severity of the first clinical presentation of
CD. All these data suggest the role of TBARS as a potential marker of the severity of the disease.
Serum TBARS levels were also correlated with smoking habit being higher in smokers and to a
lesser extent, in former smokers when compared to non-smokers. Cigarette smoke is a well-known
source of ROS and one of the most powerful oxidative stress inducers. It is considered both an
etiological risk factor for CD as well as for its recurrence; smokers have a higher risk when compared to
non-smokers of developing a postoperative recurrence and the risk increases in relation to the number
of cigarettes smoked [41,42].
We also defined an oxidative score to take into account the overall oxidative–antioxidant status of
each patient and identified positive correlations with smoking habit and the presence of cutaneous
manifestation of the disease, a well-recognized complication of IBD that frequently occurs in CD and is
associated with a worse prognosis [43,44]. The pathogenic mechanism underlying the development of
cutaneous manifestations in CD patients is still not known, but our results suggest that oxidative stress
may have a role.
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Despite the high degree of oxidative stress observed in CD patients, witnessed by the increase in
all oxidative markers measured, all correlated to each other, we did not observe differences in their
antioxidant status, measured as FRAP, when compared to controls. On the contrary, several studies
reported a reduced antioxidant capacity in CD patients, measured both as plasma carotenoids and
other vitamin content [45,46], or as total antioxidant capacity [12,47,48], or as plasma free thiols [10]. In
particular, Bourgonje and coworkers reported strong and negative correlations among albumin-adjusted
plasma free thiols and a number of pro-inflammatory markers of disease activity [10]. In this study, a
more favorable redox status was also observed in CD patients with ileal disease compared to patients
with colonic localization; in contrast, in our study, the ileal localization was significantly associated
with increased serum TBARS levels. We previously reported that disease located in the upper part of
the intestine is a risk factor for recurrence when compared to diseases located in the distal ileum and
colon [49].
The serum/plasma total antioxidant activity is the sum of the contribution of endogenous (uric acid,
bilirubin, albumin) and exogenous (medications and food-derived) antioxidants, thus this disagreement
may be due, not only to the complexity of the disease, but also to the variability in patient medications
and dietary habits or supplement use. In this context, we noted differences in AOPP values associated
with the treatment with mesalazine, known to exert anti-inflammatory and antioxidant effects, and in
the FRAP levels that were significantly higher in patients under azathioprine treatment, which may be
related to its contribution to oxidative stress [50].
Moreover, the lack of an association between circulating markers of oxidative damage and total
antioxidant capacity suggests that in CD, oxidative stress is not just the result of an imbalance between
oxidants and antioxidants, but may prime, at least in the acute phase of the disease, pro-inflammatory
mechanisms through RAGE activation.
The main limitations of this study are the relatively small sample size, the cross-sectional design,
the lack of follow-up, and of recurrent measurements during the course of the disease, which are
necessary to validate the relevance of using oxidative stress markers in the clinical setting.
5. Conclusions
Despite these limitations, our data provide evidence that circulating AOPP and TBARS levels are
significantly elevated in CD patients with severe relapse, suggesting that these parameters could be
evaluated in a prospective, larger study on the progression of CD disease, as biomarkers for diagnosis
or monitoring of CD patients. Moreover, our results indicate that AOPP/AGEs activation of RAGE
signaling should be explored for diagnostic or therapeutic purposes in immune-mediated diseases
such as CD.
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